BMCM
DGX icon

Bryn Mawr Capital Management’s Quest Diagnostics DGX Stock Holding History

Bryn Mawr Capital Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$484K Sell
2,283
-90
-4% -$17.7K 0.02% 296
2026
Q1 		$465K Buy
+2,373
New +$461K 0.02% 284
2025
Q4 		– Sell
-1,238
Closed -$236K – 453
2025
Q3 		$236K Sell
1,238
-738
-37% -$131K 0.01% 396
2025
Q2 		$355K Sell
1,976
-15
-0.8% -$2.6K 0.02% 322
2025
Q1 		$337K Buy
+1,991
New +$327K 0.02% 302

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Bryn Mawr Capital Management's DGX Position: Q2 2026 in Review

Bryn Mawr Capital Management reduced its Quest Diagnostics (DGX) stake by 3.8% in Q2 2026, selling an estimated $17.7K and leaving 2,283 shares worth $484K. The position accounts for 0.02% of the portfolio, ranked #296.

Bryn Mawr Capital Management first reported a position in DGX in Q1 2025 and has held it in 5 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Bryn Mawr Capital Management held 2,283 shares of Quest Diagnostics worth $484K as of Q2 2026.
  • Bryn Mawr Capital Management sold 90 Quest Diagnostics shares in Q2 2026, an estimated $17.7K.
  • Quest Diagnostics made up 0.02% of Bryn Mawr Capital Management's portfolio in Q2 2026, its #296 holding.
  • Bryn Mawr Capital Management first reported a position in Quest Diagnostics in Q1 2025 and has held it in 5 quarters since.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Bryn Mawr Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.